Goldman Sachs Starts Hologic (HOLX) at Buy Following Gen-Probe Deal
Tweet
Share
E-mailGet Alerts HOLX Hot Sheet
Price: $76.01 --0%
Rating Summary:
6 Buy, 28 Hold, 0 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Rating Summary:
6 Buy, 28 Hold, 0 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
Goldman Sachs removed their Not Rated designation on Hologic (NASDAQ: HOLX) and now rates share at Buy with a $24 price target, suggesting 22% upside.
The firm said Gen-Probe's (acquired by Hologic) assets "will accelerate top-line growth by 200bps via new product cycles and the strength of HOLX’s distribution." In addition, they are bullish on cost synergies and see upside to management guidance.
For an analyst ratings summary and ratings history on Hologic click here. For more ratings news on Hologic click here.
Shares of Hologic closed at $19.65 yesterday.
The firm said Gen-Probe's (acquired by Hologic) assets "will accelerate top-line growth by 200bps via new product cycles and the strength of HOLX’s distribution." In addition, they are bullish on cost synergies and see upside to management guidance.
For an analyst ratings summary and ratings history on Hologic click here. For more ratings news on Hologic click here.
Shares of Hologic closed at $19.65 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Seaport Global Securities Starts ADI Global Distribution (ADIG) at Buy
- Oppenheimer Starts Carriage Services (CSV) at Outperform
- Lake Street Starts RF Industries Ltd. (RFIL) at Buy
Create E-mail Alert Related Categories
New CoverageRelated Entities
Goldman SachsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
